A Comprehensive Study on Nerivio Migra
Migraine is one among the foremost prevalent and disabling disorders, characterized by recurrent headache attacks with nausea, vomiting, photophobia, and phonophobia. Nerivio Migra may be a breakthrough device for acute treatment of migraines. Attached to the patient's arm (below the shoulder), it's a clinically-tested wearable suited to be worn everywhere and at any time. Non steroidal anti inflammatory drugs (NSAIDs) and triptans, commonly used for acute migraine treatment3, may be ineffective, poorly tolerated, contraindicated, and if used in excess, may lead to medication overuse headache there is a great unmet need for alternative acute migraine treatments that are both effective and well tolerated. Non-invasive neuromodulation is safe, well tolerated, and may have fewer adverse effects than drugs. Remote electrical neuromodulation (REN) may be a novel acute migraine treatment that stimulates upper arm peripheral nerves to induce conditioned pain modulation (CPM)-an endogenous analgesia mechanism during which conditioning stimulation inhibits pain in remote body regions.
2. Society (IHS) HCC of the IH. The international classification of headache disorders, (beta version). Cephalalgia. 2013; 33: 629- 808
3. Silva AND, Tepper SJ. Acute treatment of migraines. CNS Drugs. 2012; 26: 823- 839.
4. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010; 9: 285- 298.
5. Diener H-C, Limmroth V. Medication-overuse headache: A worldwide problem. Lancet Neurol.2004; 3: 475- 483.
6. Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009; 13: 301- 307.
7. Katić BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to acute migraine medication: What does it mean, why does it matter? Headache. 2010; 50: 117- 129.
8. Bigal M, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009; 49: 1028- 1041.
9. Alam A, Munjal S, Reed M, et al. Triptan use and discontinuation in a representative sample of persons with migraine: Results from migraine in America symptoms and treatment (MAST) study (P4.10-019). Neurology. 2019; 92(Suppl. 15) P4.10-019.
10. Puledda F, Goadsby PJ. An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache. 2017; 57: 685- 691.
11. Starling A. Noninvasive neuromodulation in migraine and cluster headache. CurrOpin Neurol.2018; 31: 268- 273.
12. Nir R-R, Yarnitsky D. Conditioned pain modulation. CurrOpin Support Palliat Care. 2015; 9: 131- 137.
13. Yarnitsky D, Volokh L, Ironi A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017; 88: 1250- 1255.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).